Subscribe
Sign In
Tag: CBT > Cannabis DEA: Page 3
Industry Headlines
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
MMJ submitted an FDA Investigational New Drug application for a cannabis-derived medication.
December 11, 2024
Top Stories
Attorney General Undelegated DEA’s Rescheduling Authority, Lawyers Argue; Possible Stay Could Delay Hearings
The cannabis rescheduling buck stops with the DOJ head, according to attorneys arguing that the DEA administrator cannot issue the final rule.
December 5, 2024
Top Stories
DEA Counsel Dodges Question on Support for Cannabis Rescheduling
An administrative law judge asked the agency’s lead attorney the question during preliminary proceedings for an upcoming rescheduling hearing.
December 2, 2024
Top Stories
DEA Could Subpoena HHS in Cannabis Rescheduling Hearings
The Drug Enforcement Administration indicated it could target a ‘novel’ two-factor test used to determine currently accepted medical use.
November 26, 2024
Top Stories
Smart Approaches to Marijuana Responds to Claims It Colluded With DEA
The prohibitionist group says cannabis rescheduling advocates are attempting to ‘create a sideshow’ of the DEA’s hearing process.
November 25, 2024
Top Stories
DEA Denies Collusion Allegations Ahead of Cannabis Rescheduling Hearing
The DEA argues that cannabis advocates have no evidence that the agency engaged in unlawful communications with a prohibitionist group.
November 25, 2024
Top Stories
2 US House Democrats Nudge DEA to ‘Swiftly’ Reschedule Cannabis
Reps. Jerry Nadler and Frank Pallone Jr., both ranking members, wrote a letter to the attorney general and DEA administrator.
October 2, 2024
Cannabis Industry Research
Medical Marijuana Act Signed by Biden Would Hinder Research Under Rescheduling
The Medical Marijuana and Cannabidiol Research Expansion Act’s requirements would remain under Schedule III, a congressional researcher says.
September 20, 2024
Cannabis Advertising
The Complex Impact of Rescheduling Cannabis on Advertising
The penalties for advertising Schedule I drugs don’t apply to Schedule III drugs, but cannabis businesses could be left in a precarious position.
September 17, 2024
Industry Headlines
MMJ BioPharma Suing DEA Over Cannabis Reform, Medical Research
The biopharmaceutical company filed a lawsuit, citing ‘unjustified’ delays in processing an application for medical research.
September 11, 2024
Banking Bill Cannabis Industry
Trump Signals Support for Federal Cannabis Rescheduling, Banking Reform
The GOP presidential candidate said he will focus on unlocking the ‘medical uses of marijuana to a Schedule 3 drug’ if elected in November.
September 9, 2024
2018 Farm Bill Status
4th Circuit Court Rules THC-O Meets Legal Definition of Hemp, Deviating From DEA
The federal court’s interpretation of the 2018 Farm Bill contradicts the Drug Enforcement Administration’s position that THC-O is illegal.
September 9, 2024
Previous Page
Page 3 of 9
Next Page